

Federal judge swats Aetna-Humana insurer combo

January 23 2017, by Tom Murphy



This Tuesday, Aug. 19, 2014, file photo, shows signage in front of Aetna Inc.'s headquarters in Hartford, Conn. A federal judge has rejected health insurer Aetna's plan to buy rival Humana for about \$34 billion and become a major player in the market for Medicare Advantage coverage. U.S. District Judge John Bates said in an opinion filed Monday, Jan. 23, 2017, that he largely agrees with federal regulators who contended that such a combination would hurt competition. (AP Photo/Jessica Hill, File)

A federal judge has rejected health insurer Aetna's bid to buy rival



Humana on grounds that the deal would hurt competition in hundreds of Medicare Advantage markets, ultimately affecting the price consumers pay for coverage.

U.S. District Judge John Bates said in an opinion filed Monday that federal regulation would probably be "insufficient to prevent the merged firm from raising prices or reducing benefits," and neither new competitors nor an Aetna plan to sell some of the combined company's business to another insurer, Molina Healthcare Inc., would be enough to ease competitive concerns.

Aetna spokesman TJ Crawford said the insurer was reviewing the decision "and giving serious consideration to an appeal after putting forward a compelling case."

Aetna, the nation's third-largest health insurer, had announced in 2015 its plan to spend around \$34 billion on Humana Inc. and become one of the top providers in the fast-growing Medicare Advantage market. Medicare Advantage plans are privately run versions of the government's Medicare program for people who are over age 65 or disabled.

The Justice Department sued last summer to block Aetna's deal and Blue Cross-Blue Shield carrier Anthem Inc.'s separate, \$48-billion purchase of Cigna Corp. Both cases went to trial late last year. An opinion has yet to be rendered for the Anthem case.





This Aug. 8, 2011, file photo, shows the entrance to the Humana building, in Louisville, Ky. A federal judge has rejected health insurer Aetna's plan to buy rival Humana for about \$34 billion and become a major player in the market for Medicare Advantage coverage. U.S. District Judge John Bates said in an opinion filed Monday, Jan. 23, 2017, that he largely agrees with federal regulators who contended that such a combination would hurt competition. (AP Photo/Ed Reinke, File)

The two deals would consolidate the nation's five largest insurers into three, a list that includes UnitedHealth Group Inc., currently the largest.

The big insurers had argued that by getting bigger they will be able to negotiate better prices with pharmaceutical companies, hospitals and doctor groups that also are growing. They also expect to cut expenses and add more customers, which helps them better spread out the cost of investing in technology to manage and improve care.

But Bates, who is based in Washington, D.C., said in a 158-page opinion that the Aetna-Humana combination would "likely substantially lessen competition" for Medicare Advantage plans in 364 counties and, separately, in some Florida public insurance exchanges.



Deputy Assistant Attorney General Brent Snyder said in a statement that the decision was "a victory for American consumers - especially seniors and working families and individuals."

Industry experts have said any impact from the deals on consumers would take years to materialize and could lead to savings in some areas, along with the risk of higher costs elsewhere.

Shares of Hartford, Connecticut-based Aetna Inc. fell about 3 percent, or \$3.54, to \$118.99 Monday afternoon, while broader indexes slipped less than 1 percent. In contrast, Louisville, Kentucky-based Humana Inc.'s stock climbed \$3.78 to \$204.31.

© 2017 The Associated Press. All rights reserved.

Citation: Federal judge swats Aetna-Humana insurer combo (2017, January 23) retrieved 4 May 2024 from https://medicalxpress.com/news/2017-01-blocks-aetna-humana-bad-consumers.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.